Mytide's core product is the Gen2 platform, an AI-enabled, closed-loop manufacturing system that produces natural and non-natural peptides up to 30-times faster than traditional methods by integrating synthesis, analysis, purification, and lyophilization. The platform couples in-process data capture with a continuously learning AI engine to improve purity, production reliability, and speed while enabling access to difficult-to-manufacture non-canonical amino acids, constrained peptides, and short proteins. Mytide asserts it has built one of the largest and fastest-growing peptide manufacturing data repositories to support high-throughput screening, library generation, and computational biology modeling for in vivo, in vitro, and clinical studies. The company positions Gen2 for integration into cGMP environments to enable scalable, decentralized clinical-trial manufacturing of peptide-based therapeutics and personal peptide vaccines. Mytide has partnered with pharmaceutical companies for scalable, time-sensitive manufacturing across research and clinical programs. The recent financing is intended to scale the Gen2 platform and broaden access to cost-effective peptide and peptide-conjugate manufacturing.

Total raised

$7M

Funding rounds

1

Latest round

Series A

Latest activity

Mar 2022